Dashboard
Manage Tickers

ARQT Arcutis Biotherapeutics, Inc.

Nasdaq arcutis.com


$ 25.31 $ 0.39 (1.57 %)    

Friday, 31-Oct-2025 19:15:47 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 629.16 $ 3.02 (0.48 %)
DIA $ 475.58 $ 0.66 (0.14 %)
SPY $ 681.80 $ 2.23 (0.33 %)
TLT $ 90.21 $ -0.27 (-0.3 %)
GLD $ 368.20 $ -2.01 (-0.54 %)
$ 25.31
$ 24.89
$ 25.02 x 5
$ 25.80 x 200
$ 24.63 - $ 25.56
$ 8.29 - $ 27.08
2,300,159
na
3.1B
$ 0.91
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-28-2025 09-30-2025 10-Q
2 08-06-2025 06-30-2025 10-Q
3 05-06-2025 03-31-2025 10-Q
4 02-25-2025 12-31-2024 10-K
5 11-06-2024 09-30-2024 10-Q
6 08-14-2024 06-30-2024 10-Q
7 05-14-2024 03-31-2024 10-Q
8 02-27-2024 12-31-2023 10-K
9 11-03-2023 09-30-2023 10-Q
10 08-08-2023 06-30-2023 10-Q
11 05-09-2023 03-31-2023 10-Q
12 02-28-2023 12-31-2022 10-K
13 11-08-2022 09-30-2022 10-Q
14 08-04-2022 06-30-2022 10-Q
15 05-05-2022 03-31-2022 10-Q
16 02-22-2022 12-31-2021 10-K
17 11-04-2021 09-30-2021 10-Q
18 08-05-2021 06-30-2021 10-Q
19 05-06-2021 03-31-2021 10-Q
20 02-16-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 08-11-2020 06-30-2020 10-Q
23 05-12-2020 03-31-2020 10-Q
24 03-19-2020 12-31-2019 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

goldman-sachs-maintains-neutral-on-arcutis-biotherapeutics-raises-price-target-to-29
Goldman Sachs Maintains Neutral on Arcutis...
10/30/2025 15:20:52

Goldman Sachs analyst Richard Law maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Neutral and raises the price targe...

arcutis-biotherapeutics-announces-commercial-roll-out-of-zoryve-cream-to-treat-mild-to-moderate-atopic-dermatitis-in-children-ages-2-to-5-in-us
Arcutis Biotherapeutics Announces Commerci...
10/30/2025 12:01:39

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful inno...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
10/28/2025 17:06:24

crude-oil-falls-over-2-paypal-shares-spike-higher
Crude Oil Falls Over 2%; PayPal Shares Spi...
10/28/2025 16:18:17

wayfair-qorvo-celestica-united-parcel-service-regeneron-pharmaceuticals-and-other-big-stocks-moving-higher-on-tuesday
Wayfair, Qorvo, Celestica, United Parcel S...
10/28/2025 14:14:02

arcutis-biotherapeutics-q3-eps-006-beats-010-estimate-sales-99219m-beat-86978m-estimate
Arcutis Biotherapeutics Q3 EPS $0.06 Beats...
10/28/2025 12:31:21

Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate ...

earnings-scheduled-for-october-28-2025
Earnings Scheduled For October 28, 2025
10/28/2025 11:11:34

uncovering-potential-arcutis-biotherapeuticss-earnings-preview
Uncovering Potential: Arcutis Biotherapeut...
10/27/2025 19:01:24

arcutis-to-present-zoryve-data-at-2025-fall-clinical-dermatology-conference-oct-23-26
Arcutis To Present ZORYVE Data At 2025 Fal...
10/24/2025 12:01:14

fda-approves-arcutis-zoryve-cream-005-for-atopic-dermatitis-in-children-between-2-to-5
FDA Approves Arcutis' ZORYVE Cream 0.05% F...
10/06/2025 12:16:07

arcutis-to-present-new-zoryve-foam-cream-data-at-european-academy-of-dermatology-and-venereology-congress-in-paris
Arcutis To Present New ZORYVE Foam Cream D...
09/17/2025 08:38:25

arcutis-submits-snda-to-expand-zoryve-cream-use-for-plaque-psoriasis-in-children-as-young-as-2
Arcutis Submits sNDA To Expand ZORYVE Crea...
09/03/2025 15:47:15

If approved, ZORYVE cream would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as youn...

top-5-biotech-stocks-with-strong-momentum
Top 5 Biotech Stocks With Strong Momentum
08/28/2025 11:19:00

Top 5 biotech stocks jumping into the top 10% momentum this week—ADCT, ARQT, CLLS, ENTO, HOTH—amid rapid sector rallies.

needham-maintains-buy-on-arcutis-biotherapeutics-raises-price-target-to-22
Needham Maintains Buy on Arcutis Biotherap...
08/07/2025 10:34:01

Needham analyst Serge Belanger maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $...

arcutis-biotherapeutics-q2-eps-013-beats-017-estimate-sales-81504m-beat-72753m-estimate
Arcutis Biotherapeutics Q2 EPS $(0.13) Bea...
08/06/2025 20:01:25

Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate ...

Core News & Articles
Earnings Scheduled For August 6, 2025
08/06/2025 08:33:21

this-palantir-technologies-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-friday
This Palantir Technologies Analyst Begins ...
07/25/2025 12:34:15

goldman-sachs-initiates-coverage-on-arcutis-biotherapeutics-with-neutral-rating-announces-price-target-of-18
Goldman Sachs Initiates Coverage On Arcuti...
07/25/2025 10:59:53

Goldman Sachs analyst Richard Law initiates coverage on Arcutis Biotherapeutics (NASDAQ:ARQT) with a Neutral rating and ann...

arcutis-biotherapeutics-zoryve-cream-015-received-recommendation-in-focused-guideline-update-for-management-of-adult-ad-from-aad
Arcutis Biotherapeutics' ZORYVE cream 0.15...
06/26/2025 12:08:55

The American Academy of Dermatology (AAD) provided evidence-based recommendation for the use of ZORYVE® (roflumilast) cream 0.1...

arcutis-biotherapeutics-enrolls-first-child-in-phase-2-open-label-study-integument-infant-evaluating-safety-and-tolerability-of-investigational-zoryve-cream-005-in-infants-with-ad-applied-once-daily-over-a-four-week-period
Arcutis Biotherapeutics Enrolls First Chil...
06/10/2025 12:14:09

Four-week Phase 2 study to evaluate investigational, once-daily ZORYVE .05% in infants as young as 3 months to less than 2 year...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION